Announced 2027 list price cut guarantees that undated cost pages will go stale

Novo Nordisk announced on February 24, 2026 that it will cut the US list price of its semaglutide medicines to $675 per month, effective January 1, 2027 ^[1]. The change covers Wegovy (semaglutide) injection 2.4 mg and tablets 25 mg, Ozempic (semaglutide) injection 0.5 mg, 1 mg and 2 mg, and Rybelsus (semaglutide) tablets 7 mg and 14 mg, and applies to all doses of those medicines ^[1].

The company described the reductions as roughly 50% for Wegovy and about 35% for Ozempic compared with current list prices ^[1]. Novo Nordisk did not state a percentage reduction for Rybelsus in its announcement ^[1].

What the list price is, and what it isn't

List price, also called wholesale acquisition cost or WAC, is the sticker price before rebates, discounts and insurance. Novo Nordisk framed the cut as aimed at people whose out-of-pocket cost is tied directly to that number. "The lower list price is intended to connect more people with our innovative medicines, specifically those whose out-of-pocket costs are linked to list price, such as individuals with high-deductible health plans or co-insurance benefit designs," said Jamey Millar, executive vice president, US Operations of Novo Nordisk ^[1].

The announcement also says plainly that the change "does not have an impact on direct-to-patient, self-pay prices" ^[1]. That means the cash-pay channels the company already runs — including savings offers, self-pay through NovoCare Pharmacy and select telehealth relationships — are not being repriced by this move ^[1]. The press release does not list the current dollar amounts for those self-pay options, so how $675 will compare to them in 2027 is not established by this source ^[1].

Novo Nordisk also said supply of all doses of these medicines is fully available nationwide in the US, and pointed patients away from compounded copies, saying "there is no reason for patients to gamble with their health with knock-off products produced by compounders" ^[1].

Why it matters for patients

The practical effect depends heavily on how a person pays. Someone in a high-deductible plan or with coinsurance often pays a percentage of, or the full amount up to, a price anchored to WAC. For those patients, a list price drop can show up directly at the pharmacy counter ^[1]. Someone with a flat copay, or someone using a cash-pay program, may see no change at all from this specific action, since Novo Nordisk says self-pay prices are unaffected ^[1].

There is also a timing issue that is easy to miss: nothing about the price changes in 2026. The new $675 figure starts January 1, 2027 ^[1]. That gap creates a stretch of nearly a year in which published cost estimates, calculators and "how much does Wegovy cost" pages can be accurate today and wrong next year. Any price figure a patient reads without a visible date attached to it is hard to interpret. Checking when a number was last verified — and whether it refers to list price, an insured copay or a cash-pay price — is the difference between a useful figure and a misleading one.

What this announcement does not tell us: how insurers and pharmacy benefit managers will adjust formularies, deductibles or rebate arrangements in response; whether monthly out-of-pocket costs will fall by a similar percentage for any given plan; and how competing GLP-1 products will be priced. None of that is addressed in the announcement ^[1].

What happens next

• February 24, 2026: Novo Nordisk publicly announces the reduction ^[1].
• January 1, 2027: The $675 monthly list price takes effect across Wegovy, Ozempic and Rybelsus, for all doses ^[1].

Between those two dates, current list prices remain in place. Patients comparing costs during 2026 are looking at pricing that is already scheduled to change, which is a good reason to treat undated cost information with caution and to confirm the specific number that applies to a specific plan or pharmacy.

This article describes a pricing announcement only. Questions about which medicine is appropriate, at what dose, belong with a licensed clinician.